Evidence map›Paper›PMID 31641977›Full record

SynthesisHeart failure reviews2020

Circulating galectin-3 on admission and prognosis in acute heart failure patients: a meta-analysis.

Hongsen Chen, Chensong Chen, Junjie Fang, Ren Wang, Wanshui Nie

Abstract readMeta-AnalysisReview
PubMed Publisher
In one paragraph

Synthesis in Heart failure reviews, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 3 pooled it
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 3 syntheses or guidelines pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Hongsen ChenDepartment of Intensive Care Unit, The First People's Hospital of Xiangshan, No. 291 Donggu Road, Xiangshan County, Ningbo, 315700, China. chenhongsen98@163.com.ORCID 0000-0002-3399-9506
Chensong ChenDepartment of Intensive Care Unit, The First People's Hospital of Xiangshan, No. 291 Donggu Road, Xiangshan County, Ningbo, 315700, China.
Junjie FangDepartment of Intensive Care Unit, The First People's Hospital of Xiangshan, No. 291 Donggu Road, Xiangshan County, Ningbo, 315700, China.
Ren WangDepartment of Intensive Care Unit, The First People's Hospital of Xiangshan, No. 291 Donggu Road, Xiangshan County, Ningbo, 315700, China.
Wanshui NieDepartment of Intensive Care Unit, The First People's Hospital of Xiangshan, No. 291 Donggu Road, Xiangshan County, Ningbo, 315700, China.
Xiangshan County First People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Changes of serum galectin-3 have been associated with the pathogenesis of many cardiovascular diseases. The aim of the study was to evaluate the prognostic role of serum galectin-3 in patients with acute heart failure (AHF) in a meta-analysis. Follow-up studies evaluating the association between serum galectin-3 on admission and clinical outcomes in AHF patients were identified via search of PubMed and Embase databases. A random effects or a fixed effects model was applied to pool the results depending on the heterogeneity. Subgroup analysis was used to evaluate the influences of study characteristics on the outcomes. Overall, 7057 AHF patients from eighteen follow-up studies were included. Higher serum galectin-3 was associated with higher risks of all-cause mortality (adjusted risk ratio [RR], 1.58; p < 0.001), mortality/HF rehospitalization (RR, 1.68; p < 0.001), and cardiovascular mortality (RR, 1.29; p = 0.04), but not HF rehospitalization (RR, 1.24; p = 0.25) in AHF patients. Subgroup analyses showed that study characteristics including study design, sample size, age, gender, left ventricular ejection fraction, galectin-3 variable type, follow-up duration, and adjustment of type B natriuretic peptide did not significantly impact the results. Significant heterogeneities were detected for the outcomes of all-cause mortality and mortality/HF rehospitalization. However, trim-and-fill analyses by including the imputed studies to generate symmetrical funnel plots showed similar significant meta-analysis results. These results suggested that higher serum galectin-3 may be associated with poor prognosis in AHF patients. Further studies are needed to determine the mechanisms underlying the potential prognostic role of galectin-3 in AHF.

Indexed as

Acute DiseaseBiomarkersBlood ProteinsGalectinsHeart FailureHumansPrognosisStroke VolumeBiomarkersBlood ProteinsGalectinsLGALS3 protein, humanAcute heart failureGalectin-3Meta-analysisMortalityRehospitalization

Identifiers

PMID31641977
OpenAlexW2981350596

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.